Kerry LaPlante, Pharm.D.

Assistant Professor
Department of Pharmacy Practice
kerrytedesco@uri.edu

Publications | Honors & Awards

Click here for information about Dr. LaPlante's lab

Research Interests

Dr. LaPlante is currently an Assistant Professor at the University of Rhode Island’s College of Pharmacy. She completed her Doctor of Pharmacy and Post-Doctorial Fellowship in infectious diseases/pharmacotherapy at Wayne State University in Detroit Michigan. Her foremost research interest is in infectious diseases, specifically, multi drug resistant gram-positive bacteria, biofilms and toxin production. Her research laboratory and clinical practice site is located at the Veterans Affairs Medical Center in Providence, Rhode Island. In addition to Dr. LaPlante’s research interests, she is actively involved in advancing the profession of pharmacy. Dr. LaPlante was honored as the 2004 Distinguished Young Pharmacist in the state of Michigan. She has also held several leadership positions in pharmacy associations. She is published in peer-reviewed journals such as Antimicrobial Agents and Chemotherapy, Pharmacotherapy, Expert Opinion in Pharmacotherapy, and Diagnostic Microbiology and Infectious Disease and her research has been presented in Denmark, France, Czech Republic and throughout the United States.

Clinical Practice Site

Veterans Affairs Medical Center

Education

Bachelor of Science, Biology, Canisius College, Buffalo, NY, 1996

Bachelor of Science, Pharmaceutical Sciences Wayne State University, College of Pharmacy Detroit, MI, 2000

Doctor of Pharmacy, Wayne State University, College of Pharmacy Detroit, MI, 2002

Experience

Adjunct Clinical Assistant Professor of Medicine, Warren Alpert Medical School of Brown University, Department of Medicine of the Division of Biology and Medicine and Infectious Diseases, Brown University, Providence, RI; 2007 - present

Assistant Professor of Pharmacy, URI College of Pharmacy, Department of Pharmacy Practice, University of Rhode Island

Clinical Pharmacy Specialist, Infectious Diseases, Veterans Affairs Medical Center, Providence, RI

DePestel DD, Benninger M, Danziger L, LaPlante KL, May C, Luskin A, Pichichero M, Hadley JA. Cephalosporin Use in the Treatment of Penicillin-Allergic Patients; Status: in press. Journal of the American Pharmacists Association.

LaPlante KL, Rybak MJ. Andes D, Craig WA. Community Associated-Methicillin Resistant Staphylococcus aureus isolates versus Daptomycin, Clindamycin, Doxycycline, Linezolid and Trimethoprim/Sulfamethoxazole in an in vitro Pharmacodynamic model.  Antimicrob Agents Chemother. 2008 Apr 14, Eur ahead of print

LaPlante KL, Mersfelder TL, Ward KE, Quilliam, BJ. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. Pharmacotherapy. 2008 Jan;28(1):82-9.

Attwood RJ, LaPlante KL. Telavancin, a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm. 2007 Nov 15;64(22):2335-48.

LaPlante KL Mermel LA.. In Vitro Activity of Daptomycin and Vancomycin Lock Solutions on StaphylococcalBiofilms in a Central Venous Catheter Model. Nephrol. Dial. Transplant. 22: 2239-2246

LaPlante KL, Rybak MJ, Tsuji B, Lodise, T, Kaatz GW,  Fluoroquinolone Resistance in Streptococcus pneumoniae, Area Under the Curve: Minimum Inhibitory Concentration Ratio and the Probability of Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. Antimicrob Agents Chemother. 2007 Feb 12.

LaPlante KL, Rybak MJ, Amjad A, Kaatz GW.  Antimicrobial Susceptibility and Staphylococcal Chromosomal Cassette mec Type in Community- and Hospital-Associated Methicillin-Resistant Staphylococcus aureus. Pharmacotherapy. 2007 Jan;27(1):3-10.

LaPlante KL, In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 2006 Nov 30

Socha A, LaPlante KL, Rowley DR, New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates. Bioorg Med Chem. 2006 Dec 15;14(24):8446-54. Epub 2006 Sep 18

LaPlante KL, Rybak MJ, Leuthner KL, Chin JN Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob Agents Chemother. 2006 Apr;50(4):1298-303.

Ward KE, Mersfelder TL, LaPlante KL. Oritavancin--an investigational glycopeptide antibiotic.
Expert Opin Investig Drugs. 2006 Apr;15(4):417-29. Review.

Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy. 2005 Jan;25(1):74-85. Review.

LaPlante KL, Rybak MJ.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72.

LaPlante KL, Rybak, MJ. Daptomycin - a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother. 2004 Nov;5(11):2321-31. Review.

LaPlante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline.  Diagn Microbiol Infect Dis. 2004 Oct;50(2):125-30. 

Tedesco KL, Rybak MJ. Daptomycin; Drug Review.  Pharmacotherapy 2004;24 (1):41-57.